Онкологические заболевания во время беременности

1. Williams T.J., Turnbull K.E. Carcinoma in situ and pregnancy. ObstetGynecol . 1964; 24: 857–64. PMID:14244866
2. Smith L.H., Danielsen B., Allen M.E., Cress R. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. Am J Obstet Gynecol. 2003; 189(4): 1128–35. doi:10.1067/s0002-9378(03)00537-4
3. Pavlidis N.A. Coexistence of pregnancy and malignancy. Oncologist. 2002; 7; 279–287. PMID:12185292
4. Stensheim H., Moller B., van D.T., Fossa S.D. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol. 2009; 27: 45–51. doi: 10.1200/JCO.2008.17.4110.
5. Stensheim H., Moller B., van Dijk T., Fossa S.D. Cause-specifi c survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol. 2009; 27: 45–51. doi: 10.1200/JCO.2008.17.4110.
6. Murthy R.K., Theriault R.L., Barnett C.M., Hodge S., Ramirez M.M., Milbourne A., Rimes S.A., Hortobagyi G.N., Valero V., Litton J.K., et al. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Research. 2014; 16(6): 500 doi: 10.1186/s13058-014-0500-0
7. OECD Family Database. SF2.3: mean age of mothers at first childbirth. OECD – social policy division – directorate of employment, labour and social affairs. http://www.oecd.org/els/social/family/database; 2012. Ref type: online source.
8. Salani R., Billingsley C.C., Crafton S.M.. Cancer and pregnancy: an overview for obstetricians and gynecologists. Am J Obstet Gynecol. 2014; 211(1): 82. doi: 10.1016/j.ajog.2014.02.008
9. Walton J.R., Prasad M.R. Obstetric and neonatal outcomes of cancer treated during pregnancy. Clin Obstet Gynecol. 2011; 54: 567–73. doi: 10.1097/GRF.0b013e318236e781
10. Ebert U., Loffler H., Kirck W. Cytotoxic therapy and pregnancy. Pharmacol Ther. 1997; 74: 207–20. doi:10.1016/s0163-7258(97)82004-9
11. Lishner M., Avivi I., Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an International Consensus Meeting. J Clin Oncol. 2016; 34: 501–8. doi: 10.1200/JCO.2015.62.4445
12. Doll D.C., Ringenberg Q.S., Yarbro J.W. Antineoplastic agents and pregnancy. Semin Oncol 1989;16: 337–46. PMID:2678485
13. Mennes M., Stiers P., Vandenbussche E., et al. Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Pediatr Blood Cancer. 2005; 44(5): 478–86. doi:10.1002/pbc.20147
14. Kalter H., Warkany J. Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts). N Engl J Med. 1983; 308: 424–31. doi: 10.1056/NEJM198302243080804
15. Vandenbroucke T., Verheecke M., Van Calsteren K., et al. Fetal outcome after prenatal exposure to chemotherapy and mechanisms of teratogenicity compared to alcohol and smoking. Expert Opin Drug Saf. 2014; 13: 1653–65. https://doi.org/10.1517/14740338.2014.965677
16. Weibe V.J., Sipila P.E.H. Pharmacology of antineoplastic agents in pregnancy. Crit Rev Oncol Hematol. 1994;16:75-112. doi:10.1016/1040-8428(94)90043-4.
17. Cardonick E., Gilmandyar D., Somer R.A. Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy. Obstet Gynecol. 2012; 120: 1267–72. doi: http://10.1097/AOG.0b013e31826c32d9.
18. Cardonick E.H., Gringlas M.B., Hunter K., et al. Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. Am J Obstet Gynecol. 2015; 212(6): 830–1 doi: 10.1016/j.ajog.2015.01.035.
19. Amant F., Vandenbroucke T., Verheecke M., et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015; 373: 1824–34. doi: 10.1056/NEJMoa1508913
20. Bournissen G., Feig D., Koren G. Maternal–fetal transport of hypoglycemic drugs. Clin Pharmacokinet. 2003; 42: 303–13. doi:10.2165/00003088-200342040-00001
21. Gedeon C., Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta. 2006; 27: 861–8. doi:10.1016/j.placenta.2005.09.001
22. Eshkoli T., Sheiner E., Ben-Zvi Z., et al. Drug transport across the placenta. Curr Pharm Biotechnol. 2011; 12: 707–14. doi:10.2174/138920111795470877
23. Van Calsteren K., Verbesselt R., Devlieger R., et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Int J Gynecol Cancer. 2010; 20: 1456–64. doi: 10.1111/IGC.0b013e3181fb18c8.
24. Van Calsteren K., Verbesselt R., Beijnen J., et. al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxycyclophosphamide in a baboon model. Gynecol Oncol. 2010; 119: 594–600. doi: 10.1016/j.ygyno.2010.08.019.
25. Van Calsteren K., Verbesselt R, Ottevanger N., et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scandinavica. 2010; 89: 1338–45. doi: 10.3109/00016349.2010.512070.
26. Mhallem Gziri M., Han S.N. Tongue cancers during pregnancy: case reports and review of literature. Head Neck. 2013; 35(4): 102–8. doi: 10.1002/hed.21924.
27. Langagergaard V. Birth outcome in women with breast cancer, cutaneous malignant melanoma, or Hodgkin’s disease: a review. Clin Epidemiol. 2010; 3: 7–19. doi: 10.2147/CLEP.S12190.
28. Reynoso E.E., Shepherd F.A., Messner H.A., et al. Acute leukemia during pregnancy: the Toronto leukemia study group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol. 1987; 5: 1098–106. doi:10.1200/JCO.1987.5.7.1098
29. Val Calsteren K., Heyns L., De Smet F., et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 2010;28:683–9. doi: 10.1200/JCO.2009.23.2801.
30. Hahn K.M., Johnson P.H., Gordon N., et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107: 1219–26. doi:10.1002/cncr.22081
31. Giacalone P.L., Laffargue F., Benos P. Chemotherapy for breast carcinoma during pregnancy: a French national survey. Cancer 1999; 86: 2266–72. PMID:10590367
32. Aviles A., Neri N. Hematologic malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma. 2001; 2: 173–7. https://doi.org/10.3816/CLM.2001.n.023
33. Cardonick E., Usmani A., Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol. 2010; 33: 221–8. doi: 10.1097/COC.0b013e3181a44ca9
34. Buekers T.E., Lallas T.A. Chemotherapy in pregnancy. Obstet Gynecol Clin North Am. 1998; 25: 323–329. https://doi.org/10.1016/S0889-8545(05)70007-3.
35. Cardonick E., Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004; 5: 283–91. doi:10.1016/S1470-2045(04)01466-4
36. Udink ten Cate F.E., ten Hove C.H., Nix W.M., et al. Transient neonatal myelosuppression after fetal exposure to maternal chemotherapy. Case report and review of the literature. Neonatology 2009; 95: 80–5. doi: 10.1159/000151759.
37. Klink D.T., van Elburg R.M., Schreurs M.W., et al. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008; 2008: 271363. doi: 10.1155/2008/271363.
38. Friedrichs B., Tiemann M., Salwender H., et al. The effect of rituximab treatment during pregnancy on a neonate. Haematologica 2006; 91: 1426–7. PMID:16963391
39. Decker M., Rothermundt C., Hollander G., et al. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol. 2006; 7: 693–4. doi:10.1016/S1470-2045(06)70797-5
40. Murthy R.K., Theriault R.L., Barnett C.M., Hodge S., Ramirez M.M., Milbourne A., Rimes S.A., Hortobagyi N. G., Valero V., Litton J.K. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res. 2014; 16(6): 500. doi 10.1186/s13058-014-0500-0

41. Волочаева М.В., Шмаков Р.Г., Зубков В.В. Здоровье детей, рожденных женщинами с раком молочной железы, связанным с беременностью. Акушерство и Гинекология. 2014; 7: 33–7.

42. Макиева М.И., Матвеева Н.К., Ванько Л.В., Цой Т.А., Жукова А.С. Клинико-иммунологическая характеристика новорожденных у матерей с онкологическими заболеваниями. Акушерство и Гинекология. 2017; 11: 92–9.

43. Amant F., Van Calsteren K., Halaska M.J., et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncology. 2012; 13: 256–64. PMID: 22326925
44. Sawyer D.B., Peng X., Chen B., et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010; 53:105–13. doi: 10.1016/j.pcad.2010.06.007.
45. Gziri M.M., Amant F., Debiève F., et al. Effects of chemotherapy during pregnancy on the maternal and fetal heart. Prenat Diagn. 2012; 32: 614–9. doi: 10.1002/pd.3847.
46. Mulrooney D.A., Yeazel M.W., Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009; 339: b4606. doi: 10.1136/bmj.b4606.
47. Han S.N., Kesic V.I., Van Calsteren K., et al. Cancer in pregnancy: a survey of current clinical practice. Eur J Obstet Gynecol Reprod Biol. 2013; 167: 18–23. doi: 10.1016/j.ejogrb.2012.10.026.
48. Khashu M., Narayanan M., Bhargava S., Osiovich H. Perinatal outcomes associated with preterm birth at 33–36 weeks’ gestation: a population-based cohort study. Pediatrics 2009; 123: 109–13. doi: 10.1542/peds.2007-3743.
49. Saigal S., Doyle L.W. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008; 371: 261–9. doi: 10.1016/S0140-6736(08)60136-1.

50. Boyle J.D., Boyle E.M. Born just a few weeks early: does it matter? Archives of Disease in Children Fetal and Neonatal Edition 2011

51. Maggen C., Dierickx D., Lugtenburg P., Laenen A., et al. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. Lancet Haematol. 2019; 6(11): 551–61.doi:10.1016/S2352-3026(19)30195-4

Поступила 01.04.2019

Принята в печать 04.10.2019